Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XCUR - EXICURE, INC.

IEX Last Trade
5.7
0   0%

Share volume: 0
Last Updated: Fri 20 Dec 2024 09:18:23 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.46%

PREVIOUS CLOSE
CHG
CHG%
$5.70
11.80
0.67%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
26%
Profitability 25%
Dept financing 6%
Liquidity 50%
Performance 25%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.76%
1 Month
1.58%
3 Months
363.28%
6 Months
5,557.58%
1 Year
2,877.67%
2 Year
1,178.77%
Key data
Stock price
$5.70
P/E Ratio 
12.54
DAY RANGE
$5.70 - $17.50
EPS 
$0.26
52 WEEK RANGE
$0.31 - $36.00
52 WEEK CHANGE
$2,877.67
MARKET CAP 
17.043 M
YIELD 
N/A
SHARES OUTSTANDING 
8.651 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
-0.46
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$94,609
AVERAGE 30 VOLUME 
$559,951
Company detail
CEO: Matthias G. Schroff
Region: US
Website: exicuretx.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Exicure, Inc. develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders.

Recent news